Disease progression and costs of care in Alzheimer's disease patients treated with donepezil: a longitudinal naturalistic cohort.
(2012) In European Journal of Health Economics 13(5). p.561-568- Abstract
- BACKGROUND/AIMS: Improved data and methods are needed for modeling disease progression in Alzheimer's disease (AD) for economic evaluation of treatments. The aim is to estimate prediction models for long-term AD progression and subsequently economic outcomes.
METHODS: Three-year follow-up data on 435 patients treated with the cholinesterase inhibitor donepezil in clinical practise were analyzed. Regression models were estimated for long-term prediction of decline in cognitive function (ADAS-cog) and activities in daily living (ADL) ability, risk of institutionalization and costs of care.
RESULTS: The cognitive deterioration was estimated at between 1.6 and 4 ADAS-cog points per every 6 months,... (More) - BACKGROUND/AIMS: Improved data and methods are needed for modeling disease progression in Alzheimer's disease (AD) for economic evaluation of treatments. The aim is to estimate prediction models for long-term AD progression and subsequently economic outcomes.
METHODS: Three-year follow-up data on 435 patients treated with the cholinesterase inhibitor donepezil in clinical practise were analyzed. Regression models were estimated for long-term prediction of decline in cognitive function (ADAS-cog) and activities in daily living (ADL) ability, risk of institutionalization and costs of care.
RESULTS: The cognitive deterioration was estimated at between 1.6 and 4 ADAS-cog points per every 6 months, increasing with disease severity. Cognitive function was an important predictor of ADL-ability, which itself was the most important predictor of the risk of institutionalization and costs of care. Combining all models in a cross-validation process generated accurate predictions of costs of care at each 6 months follow-up.
CONCLUSION: The proposed methods for representing AD progression and economic outcomes can be used in micro-simulation models for the economic evaluation of new treatments. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/3046737
- author
- Gustavsson, Anders ; Jönsson, Linus ; Parmler, Johan ; Andreasen, Niels ; Wattmo, Carina LU ; Wallin, Åsa LU and Minthon, Lennart LU
- organization
- publishing date
- 2012
- type
- Contribution to journal
- publication status
- published
- subject
- in
- European Journal of Health Economics
- volume
- 13
- issue
- 5
- pages
- 561 - 568
- publisher
- Springer
- external identifiers
-
- wos:000308029500004
- scopus:84865622054
- pmid:21822729
- ISSN
- 1618-7601
- DOI
- 10.1007/s10198-011-0334-y
- language
- English
- LU publication?
- yes
- id
- d8953f60-85cf-425a-89e4-14b4a6901a1d (old id 3046737)
- date added to LUP
- 2016-04-01 10:28:07
- date last changed
- 2022-05-13 17:17:53
@article{d8953f60-85cf-425a-89e4-14b4a6901a1d,
abstract = {{BACKGROUND/AIMS: Improved data and methods are needed for modeling disease progression in Alzheimer's disease (AD) for economic evaluation of treatments. The aim is to estimate prediction models for long-term AD progression and subsequently economic outcomes.<br/><br>
<br/><br>
METHODS: Three-year follow-up data on 435 patients treated with the cholinesterase inhibitor donepezil in clinical practise were analyzed. Regression models were estimated for long-term prediction of decline in cognitive function (ADAS-cog) and activities in daily living (ADL) ability, risk of institutionalization and costs of care.<br/><br>
<br/><br>
RESULTS: The cognitive deterioration was estimated at between 1.6 and 4 ADAS-cog points per every 6 months, increasing with disease severity. Cognitive function was an important predictor of ADL-ability, which itself was the most important predictor of the risk of institutionalization and costs of care. Combining all models in a cross-validation process generated accurate predictions of costs of care at each 6 months follow-up.<br/><br>
<br/><br>
CONCLUSION: The proposed methods for representing AD progression and economic outcomes can be used in micro-simulation models for the economic evaluation of new treatments.}},
author = {{Gustavsson, Anders and Jönsson, Linus and Parmler, Johan and Andreasen, Niels and Wattmo, Carina and Wallin, Åsa and Minthon, Lennart}},
issn = {{1618-7601}},
language = {{eng}},
number = {{5}},
pages = {{561--568}},
publisher = {{Springer}},
series = {{European Journal of Health Economics}},
title = {{Disease progression and costs of care in Alzheimer's disease patients treated with donepezil: a longitudinal naturalistic cohort.}},
url = {{http://dx.doi.org/10.1007/s10198-011-0334-y}},
doi = {{10.1007/s10198-011-0334-y}},
volume = {{13}},
year = {{2012}},
}